Zhen Ma | Surgical Oncology | Best Researcher Award

Dr. Zhen Ma | Surgical Oncology | Best Researcher Award

Chief Resident from The Second Hospital of Lanzhou University, China

Dr. Zhen Ma is a skilled surgical oncologist specializing in gastrointestinal malignancies with advanced training in minimally invasive and robotic surgical procedures. His professional practice centers at The Second Hospital of Lanzhou University, a Grade A tertiary institution in China, where he leads surgical interventions in gastric, hepatic, and colorectal cancers. In addition to his clinical responsibilities, Dr. Ma is a dedicated researcher whose work explores resistance mechanisms in gastrointestinal tumors and innovations in surgical technology. He has authored over seven first-author publications in reputable peer-reviewed journals, contributing to the growing body of knowledge in oncology and surgical techniques. Furthermore, Dr. Ma has played key roles in more than 16 phase I–III clinical trials related to advanced solid tumors, demonstrating his expertise in clinical trial management and cancer therapeutics. His ability to integrate clinical expertise with research insights positions him as an emerging leader in surgical oncology. He is fluent in medical English, possesses extensive training in research methodologies, and actively contributes to the evolution of cancer care in China. With ongoing involvement in national research projects, clinical innovations, and the development of surgical devices, Dr. Ma exemplifies the qualities of a modern clinician-scientist committed to translational medicine and precision oncology.

Professional Profile

Education

Dr. Zhen Ma has pursued a rigorous academic pathway that reflects his dedication to excellence in medicine and oncology. He earned his Bachelor of Medicine (B.M.) in Clinical Medicine from Wuhan University (2006–2011), one of China’s top medical institutions. Following this, he completed a Master of Medicine (M.M.) in Surgery at the prestigious Zhejiang University from 2012 to 2015, where he deepened his surgical skills and began his early clinical work. His academic journey culminated with a Ph.D. in Oncology, with a focus on digestive tract tumors, from Lanzhou University (2019–2024), an institution known for its cancer research in northwest China. His doctoral research has concentrated on chemoresistance mechanisms and autophagy-related genes in gastric cancer. Each academic phase has equipped Dr. Ma with a solid foundation in clinical medicine, advanced surgical practice, and scientific research. His education reflects a balance between practical surgical expertise and a sophisticated understanding of molecular oncology. By pursuing advanced degrees from diverse top-tier universities, Dr. Ma has gained a multidisciplinary academic background that enhances his ability to approach oncological challenges from both a clinical and research perspective.

Professional Experience

Dr. Zhen Ma has cultivated a comprehensive professional background as a practicing surgical oncologist and academic researcher. He began his medical career as a surgeon at The Second Hospital of Lanzhou University in 2015, where he initially focused on thyroid oncology using minimally invasive approaches. In 2018, he advanced to the position of attending surgeon in the Department of Surgical Oncology, specializing in the surgical management of gastric, colorectal, hepatic, and biliary tract cancers. He is proficient in Enhanced Recovery After Surgery (ERAS) protocols, which have significantly improved patient outcomes, reducing complications by 30%. He also pioneered the clinical use of indocyanine green (ICG) fluorescence navigation for bilioenteric anastomosis, lowering leakage rates to below 2%. In addition to his surgical work, Dr. Ma has inserted and maintained over 100 venous infusion ports to facilitate chemotherapy for cancer patients. His professional practice is marked by a blend of innovative surgical intervention, commitment to patient safety, and continuous adoption of cutting-edge techniques. He has also served as the lead surgeon in device innovation trials and co-investigator on national-level oncology research projects, illustrating his seamless integration of clinical excellence with medical innovation and translational research.

Research Interests

Dr. Zhen Ma’s research interests are rooted in gastrointestinal oncology, with a specific focus on molecular mechanisms of chemoresistance, autophagy-related gene signatures, and minimally invasive surgical innovations. His doctoral work investigates how autophagy influences prognosis and treatment outcomes in gastric and hepatocellular carcinomas. Dr. Ma is deeply engaged in translational research that bridges molecular biology with clinical application, exemplified by his participation in studies exploring gene markers for drug resistance and survival prediction. Additionally, he has developed an interest in robotic and laparoscopic techniques as part of enhancing surgical precision and patient recovery. His participation in numerous clinical trials, including phase III studies on SOX-based chemotherapy regimens and targeted immunotherapy agents such as camrelizumab, reflects his dedication to integrating novel systemic therapies into surgical oncology. Another critical area of his research includes medical device innovation, where he led clinical trials on laparoscopic endoscopic systems for splenectomy and thyroid surgery. Overall, Dr. Ma’s research demonstrates a comprehensive approach to cancer care that includes genetics, clinical treatment optimization, and real-time surgical navigation—all aimed at improving survival rates and quality of life for gastrointestinal cancer patients.

Research Skills

Dr. Zhen Ma possesses a strong portfolio of technical and research skills that support his role as a clinician-scientist. Technically, he is adept at laparoscopic and robotic surgical techniques, ICG fluorescence imaging, thyroidectomy, and venous port placement, which are core to his surgical oncology practice. On the research side, Dr. Ma is proficient in clinical trial design and execution, supported by his Good Clinical Practice (GCP) certification. He is skilled in molecular biology techniques that include autophagy-related gene analysis and immunological assessments—crucial for understanding tumor behavior and therapy resistance. In data analysis, Dr. Ma uses software such as SPSS and R for biostatistical modeling, survival analysis, and interpretation of clinical data. He also has experience drafting case reports, literature reviews, and scientific papers for international journals. His language proficiency in both Mandarin and medical English allows him to collaborate across institutions and contribute to global research discourse. These skills make him well-equipped to design impactful studies, evaluate complex datasets, and implement innovative surgical and medical interventions with academic rigor and ethical integrity.

Awards and Honors

Although specific national or international awards are not listed in the available information, Dr. Zhen Ma’s career achievements reflect honors of clinical innovation and research leadership. Notably, he is the lead inventor of two patents: one for an abdominal belt to prevent drainage tube compression, and another for a nutrition tube unblocking device, both granted in 2020. These inventions show his ability to translate bedside challenges into tangible medical devices, which is a hallmark of applied medical innovation. Additionally, his successful participation as a Principal Investigator (PI) and Sub-Investigator (Sub-I) in high-level multicenter clinical trials reflects recognition from the national research community and pharmaceutical collaborators. His role in government-funded research projects, such as the National Health Commission GI Tumor Lab and the NSFC dual liver transplant immunology study, signifies peer trust and institutional acknowledgment of his research capacity. Furthermore, his appointment as an attending surgeon at a Grade A tertiary hospital at a relatively early stage in his career highlights the institutional confidence in his clinical and academic capabilities. These achievements position him as an award-worthy researcher contributing meaningfully to clinical practice and surgical science.

Conclusion

Dr. Zhen Ma is a dedicated and forward-thinking surgical oncologist who integrates clinical excellence with research-driven innovation. With an academic background from top Chinese universities and clinical experience at a leading tertiary care hospital, he has built a robust foundation in both patient care and medical science. His research in autophagy and chemoresistance contributes valuable insights to gastrointestinal cancer management, while his involvement in clinical trials bridges cutting-edge therapies with real-world application. His technical innovations, including ICG-guided surgery and patented medical devices, further demonstrate his commitment to enhancing patient outcomes through practical solutions. Dr. Ma’s work exemplifies the principles of translational medicine—moving from bench to bedside with measurable impact. Though early in his academic career, he has already achieved notable success in publications, research leadership, and surgical outcomes. With potential for expanded international collaboration and high-impact research publication, Dr. Ma is well-positioned to continue advancing the field of surgical oncology. As such, he represents an ideal candidate for the Best Researcher Award, honoring both his past accomplishments and his promising future contributions to medicine and clinical science.

Publications Top Notes

1. Comparative investigation of early-onset gastric cancer
Authors: Ma Z, Liu X, Paul ME, Chen M, Zheng P, Chen H
Year: 2021

2. Real-time indocyanine green fluorescence technique reduces anastomotic leakage in bilioenteric anastomosis: A case report and literature review
Authors: Ma Z, Deng J, Ma B, Chen H
Year: 2023

3. Identification and verification of a prognostic autophagy-related gene signature in hepatocellular carcinoma
Authors: Ma Z, Chen M, Liu X, Cui H
Year: 2024

4. Robotic Versus Total Laparoscopic Splenectomy With Pericardial Devascularisation for Portal Hypertension: A Retrospective Cohort Study
Authors: Ma Z, Cui H, Gaoi L, Ma B, He P, Yu Y, Wang Y, Ma Y, Chen H
Year: 2025

5. Prevention of ERCP complications
Authors: Ma Z, Li X, et al.
Year: 2019

6. Liver transplantation in primary sclerosing cholangitis
Authors: Ma Z, Tao P, et al.
Year: 2018

Berta Mosleh | Thoracic Surgery | Best Researcher Award

Dr. Berta Mosleh | Thoracic Surgery | Best Researcher Award

Department of Thoracic Surgery from Medical University of Vienna, Austria.

Berta Mosleh, MD, MSc, is a dedicated medical professional with a strong background in thoracic surgery and oncological research. She is currently pursuing a Doctoral Programme in Applied Medical Science at the Medical University of Vienna, focusing on inflammatory proteins and growth factors as biomarkers in malignant pleural mesothelioma. With a medical degree from the Medical University of Vienna and a master’s in economics from Corvinus University of Budapest, she combines clinical expertise with analytical skills. Dr. Mosleh has extensive experience in thoracic surgery, lung cancer research, and minimally invasive surgical procedures. She has contributed significantly to medical literature, with multiple peer-reviewed publications exploring the molecular and clinical aspects of thoracic malignancies. Through her work at Vienna General Hospital and involvement in various research programs, she has gained expertise in interventional bronchoscopy, cytoreductive surgery, and hyperthermic intrathoracic chemotherapy. Her research interests include oncological biomarkers, immunotherapy, and sex-based differences in lung cancer susceptibility. Dr. Mosleh’s commitment to advancing thoracic oncology has earned her recognition in the medical community. With a passion for research and innovation, she strives to enhance treatment strategies and patient outcomes in thoracic malignancies.

Professional Profile

Education

Dr. Berta Mosleh has a multidisciplinary academic background spanning medicine and economics. She is currently enrolled in the Doctoral Programme of Applied Medical Science at the Medical University of Vienna, where she is researching biomarkers for malignant pleural mesothelioma. She obtained her Doctor of Medicine (MD) degree from the Medical University of Vienna in 2019, equipping her with extensive clinical knowledge and surgical expertise. Before transitioning into medicine, Dr. Mosleh earned a Master’s degree in Economics from Corvinus University of Budapest, specializing in Business Administration and Financial Accounting. This diverse academic foundation provides her with a unique perspective on healthcare management and medical research. Throughout her education, she has engaged in numerous internships and research projects, solidifying her expertise in thoracic oncology, minimally invasive surgery, and pulmonary disease management. Her dedication to academic excellence is evident in her ongoing pursuit of medical advancements through research and clinical practice.

Professional Experience

Dr. Berta Mosleh has accumulated a wealth of experience in thoracic surgery and research. Since October 2019, she has been a surgical resident at Vienna General Hospital’s Department of Thoracic Surgery, where she actively participates in the “Thoracic Malignancies Research Program” and the “Malignant Pleural Mesothelioma Treatment and Research Program.” She previously served as a surgical and research intern at the same institution, gaining hands-on experience in minimally invasive procedures and oncological treatments. Dr. Mosleh has also contributed to research in general surgery and pulmonology, undertaking internships in internal medicine, orthopedic surgery, and reconstructive surgery. Her early career included positions in business consulting as a risk advisor at Ernst & Young and a financial auditor at Deloitte. This diverse professional background complements her medical expertise, enhancing her ability to analyze complex healthcare data and optimize clinical decision-making. Her commitment to thoracic oncology and continuous learning makes her an asset in both clinical and research settings.

Research Interests

Dr. Berta Mosleh’s research interests center on thoracic oncology, with a focus on malignant pleural mesothelioma, lung cancer, and pleural disease. She is particularly interested in identifying biomarkers for early diagnosis and treatment response in thoracic malignancies. Her research explores inflammatory proteins, growth factors, and immune checkpoint inhibitors to improve therapeutic strategies. Dr. Mosleh also investigates sex-based differences in lung cancer susceptibility and genetic alterations, aiming to refine personalized treatment approaches. Another key area of her research is the role of immunotherapy and targeted treatments in lung cancer and mesothelioma. Her work extends to the assessment of PD-1 and PD-L1 expression in lung cancer, evaluating their impact on disease progression and patient survival. Through her involvement in multiple studies, she aims to bridge the gap between experimental findings and clinical applications, ultimately improving patient care in thoracic oncology.

Research Skills

Dr. Berta Mosleh possesses a strong skill set in both clinical and laboratory research. She has expertise in biomarker analysis, molecular diagnostics, and immunohistochemistry, allowing her to study disease mechanisms at a cellular level. Her proficiency in clinical trial design and statistical analysis enables her to conduct high-quality medical research. She is skilled in various thoracic surgery techniques, including minimally invasive procedures, interventional bronchoscopy, and cytoreductive surgery. Dr. Mosleh is also adept at medical writing and has authored several peer-reviewed publications. Her ability to collaborate with interdisciplinary teams has been instrumental in advancing research projects. Additionally, her background in economics and data analysis enhances her capacity to assess healthcare trends and optimize treatment strategies. With a strong foundation in both clinical and translational research, she continues to contribute to advancements in thoracic oncology and surgical innovation.

Awards and Honors

Dr. Berta Mosleh has received recognition for her contributions to thoracic surgery and cancer research. Her work in identifying biomarkers for malignant pleural mesothelioma has been acknowledged in academic conferences and peer-reviewed journals. She has been invited to present her findings at prestigious medical symposiums, such as the ÖGP | OGTC Jahrestagung and Cancer Update CCC Vienna. Her research on sex-based differences in lung cancer susceptibility has gained attention within the scientific community. Additionally, her role in evaluating PD-1 and PD-L1 expression in lung cancer has contributed to understanding tumor immunology. Dr. Mosleh’s dedication to medical innovation and patient-centered research has earned her respect among colleagues and mentors. As she continues her research in thoracic oncology, she remains committed to furthering advancements in cancer diagnosis and treatment.

Conclusion

Dr. Berta Mosleh is a highly accomplished thoracic surgeon and researcher, dedicated to advancing the understanding and treatment of lung cancer and malignant pleural mesothelioma. With a solid academic foundation, extensive surgical experience, and a passion for oncological research, she has made significant contributions to the medical field. Her expertise in biomarker discovery, immunotherapy, and minimally invasive procedures positions her at the forefront of thoracic oncology. Through her commitment to scientific research and patient care, Dr. Mosleh continues to drive innovation in cancer treatment. Her ability to integrate clinical practice with research findings ensures that her work has a tangible impact on improving patient outcomes. As she progresses in her career, she remains dedicated to enhancing diagnostic tools, refining therapeutic strategies, and mentoring future medical professionals.

Publications Top Notes

  1. Title: Sex-based differences in lung cancer susceptibility and molecular genetics in the 2020s

    • Authors: B.O. Mosleh, Berta O.; P. Sarova, Pavla; S. Zehetmayer, Sonja; M.A. Hoda, Mir Alireza; D.R. Gompelmann, Daniela Rosa
    • Year: 2025
  2. Title: The impact of restricted chests on long-term lung function parameters following lung transplantation in patients with interstitial lung disease

    • Authors: K. Nakanishi, Keita; T. Schweiger, Thomas; S. Schwarz, Stefan; T.F. Chen-Yoshikawa, Toyofumi Fengshi; K. Hoetzenecker, Konrad
    • Year: 2025
    • Citations: 1